| Company Name: | Arrowhead Research Corporation | | Ticker Symbol: | ARWR | | | WWW Address: | www.arrowheadresearch.com |
| CEO: | Dr. Christopher Anzalone,PhD | | No. of Employees: | 52 |
| Common Issue Type: | CS | | Business Description: | Arrowhead Research Corporation is a development stage nanotechnology holding company that forms, acquires, and operates subsidiaries commercializing innovative nanotechnologies.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.318 |  0.128 | 2.02 | 2.32 | 2.17 | 2.39 | 2.17 | 140866 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 72.6 | 31.3 | 1.77 | -1.90 | 0.00 | 0.0 | 0.0 | 4.50 - 1.65 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.31 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 72.6 | mil |
| Latest Shares Outstanding | 31.3 | mil |
| Earnings pS (EPS) | -1.90 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 2,825 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 17.0 | mil |
| Float as % of Shares Outstanding | 99.1 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 4,735.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 2,365.70 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -205.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -391.1 | % |
| Current Ratio | 0.5 | |
| Leverage Ratio (Assets/Equity) | 2.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.44 | |
| LT Debt/Total Capital | 19.0 | % |
| Working Capital pS | -0.11 | $ |
| Cash pS | 0.11 | $ |
| Book-Value pS | 0.17 | $ |
| Tangible Book-Value pS | 0.02 | $ |
| Cash Flow pS | -0.76 | $ |
| Free Cash Flow pS | -0.54 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 13.61 | |
| Price/Tangible Book Ratio | 106.89 | |
| Price/Cash Flow | -3.0 | |
| Price/Free Cash Flow | -4.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.8 | 100 | 937 | 3,955 |
| 4 Weeks | 2.47 | 1.65 | 1.74 | 32.8 | 124 | 860 | 17,206 |
| 13 Weeks | 2.70 | 1.65 | 1.81 | 27.6 | 116 | 1,316 | 82,921 |
| 26 Weeks | 2.97 | 1.65 | 2.24 | 3.1 | 84 | 1,047 | 129,844 |
| 52 Weeks | 4.50 | 1.65 | 4.23 | -45.4 | 42 | 747 | 185,904 |
| YTD | 2.70 | 1.65 | - | 7.9 | 92 | 1,097 | 104,233 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.27 | 2.18 | 2.07 | 2.13 | 2.31 | 1.77 | 1.75 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -40.97 | 70.2 | -46.99 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 242.77 |
| R&D | -20.18 | NA | 24.73 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 267.3 | 40.0 | -50.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.01 | 0.09 | -1.50 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 7.50 |
| Current Ratio | 1.2 |
| Quick Ratio (Acid Test) | 1.1 |
| Liquidity Ratio (Cash) | 0.65 |
| Receivables Turnover | 0.1 |
| Average Collection Period | 3,600 |
| Working Capital/Equity | 12.4 |
| Working Capital pS | 0.09 |
| Cash-Flow pS | -1.50 |
| Free Cash-Flow pS | -1.16 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 0.46 |
| Financial Leverage Ratio (Assets/Equity) | 1.7 |
| Debt Ratio | 39.4 |
| Total Debt/Equity (Gearing Ratio) | 0.23 |
| LT Debt/Equity | 0.21 |
| LT Debt/Capital Invested | 9.8 |
| LT Debt/Total Liabilities | 32.6 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 18.84 |
| Tobin's Q Ratio | 4.38 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.90 |
| Enterprise Value (EV)/Free Cash Flow | -4.39 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 106.89 |
| Price/Book Ratio - LTM | 13.61 |
| Price/Cash Flow Ratio | -3.0 |
| Price/Free Cash Flow Ratio - LTM | -4.3 |
| Price/Sales Ratio | 245.61 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.16 |
| Current Liabilities pS | 0.39 |
| Tangible Book Value pS - LTM | 0.02 |
| Book Value pS - LTM | 0.17 |
| Capital Invested pS | 0.39 |
| Cash pS - LTM | 0.11 |
| Cash Flow pS - LTM | -0.76 |
| Free Cash Flow pS - LTM | -0.54 |
| Earnings pS (EPS) | -1.90 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -10,688.71 |
| Free Cash Flow Margin 5YEAR AVG | -3,379.15 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.01 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.01 |
| Return on Capital Invested (ROCI) | -182.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -149.1 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -133.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -113.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 6,043 |
| Revenue per Employee | 2,825 |
| Net Income per Employee | -425,206 |
| Average Collection Period | 6,043 |
| Receivables Turnover | 0.1 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 597.78 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.12 |
| Fixed Assets Turnover | 0.01 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.04 |
| Revenue per $ Plant | 0.03 |
| Revenue per $ Common Equity | 0.01 |
| Revenue per $ Capital Invested | 0.01 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 9597.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1062.2 |
| Research & Devlopment (R&D) as % of Revenue | 3670.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 3670.8 |
|
|  
|
| |
 |  |
